{"id":"NCT04180163","sponsor":"Shire","briefTitle":"Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)","officialTitle":"A Phase 3 Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Lanadelumab (SHP643) in Japanese Subjects With Hereditary Angioedema","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-12-12","primaryCompletion":"2021-08-26","completion":"2021-08-26","firstPosted":"2019-11-27","resultsPosted":"2022-09-19","lastUpdate":"2022-09-30"},"enrollment":12,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hereditary Angioedema (HAE)"],"interventions":[{"type":"DRUG","name":"Lanadelumab","otherNames":["DX-2930","TAK-743","SHP643"]}],"arms":[{"label":"Lanadelumab 300 mg q2w or q4w","type":"EXPERIMENTAL"}],"summary":"The purpose of this phase 3, open-label, multi-center study is to evaluate the safety and efficacy of lanadelumab in Japanese participants with HAE Type I or II.","primaryOutcome":{"measure":"Number of Participants Achieving Attack-Free Status for the Efficacy Evaluation Period of Day 0 Through Day 182","timeFrame":"Day 0 through Day 182","effectByArm":[{"arm":"Lanadelumab 300 mg q2w or q4w","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":11},"locations":{"siteCount":12,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5f6b5fdc4db2bf003ab472fb"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":12},"commonTop":["Hereditary angioedema","Injection site reaction","Headache","Vomiting","Injection site erythema"]}}